These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 36199208)

  • 1. [Re-Administration of Pembrolizumab for Urothelial Carcinoma after immune-Related Myasthenia Gravis : A Case Report].
    Kurokawa M; Shimizu K; Kitabayashi R; Ogawa K; Okada Y; Kubo K; Yamaguchi D; Okubo K
    Hinyokika Kiyo; 2022 Sep; 68(9):295-300. PubMed ID: 36199208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Fatal Case of Immune Checkpoint Inhibitor-Mediated Myasthenia Gravis, Myositis, and Cardiomyopathy Overlap Syndrome in Urothelial Carcinoma.
    Newman MT; Bikhchandani M
    Cancer Rep (Hoboken); 2024 Jul; 7(7):e2140. PubMed ID: 39041627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab-induced myasthenia gravis: A fatal case report.
    March KL; Samarin MJ; Sodhi A; Owens RE
    J Oncol Pharm Pract; 2018 Mar; 24(2):146-149. PubMed ID: 28147928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing suspected myasthenia gravis and myositis induced by pembrolizumab in a Jehovah's Witness sarcoma patient.
    Hutchinson A; Eskens D; Chan A; Bhargava A; Bycroft R
    J Oncol Pharm Pract; 2024 Jul; 30(5):950-953. PubMed ID: 38523425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case Report.
    Botta C; Agostino RM; Dattola V; Cianci V; Calandruccio ND; Bianco G; Mafodda A; Maisano R; Iuliano E; Orizzonte G; Mazzacuva D; Falzea AC; Saladino RE; Giannicola R; Restifo G; Aguglia U; Caraglia M; Correale P
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spontaneous development of myasthenia gravis and myositis following treatment with pembrolizumab: a case report.
    Kiaei B; Chaudhry M; Banerjee S; Brewer J; Chen Y; Khasiyev F; Guzman MA; Hayat G
    BMC Neurol; 2024 Jun; 24(1):184. PubMed ID: 38824498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A Case of Metastatic Ureteral Cancer Treated with Pembrolizumab without Relapse of Ocular Myasthenia Gravis].
    Hara S; Honda M; Kawaharada A; Nakazono M; Onuma H; Yamada H; Kiyota H; Egawa S
    Hinyokika Kiyo; 2022 Dec; 68(12):377-383. PubMed ID: 36627771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis.
    Moradi LA; Clark CA; Schneider CS; Deshane AS; Dobelbower MC
    Front Immunol; 2021; 12():788499. PubMed ID: 34956219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
    Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
    Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myasthenia gravis due to anti-PD-1 treatment for an advanced colon cancer patient: a case report and literature review.
    Yu H; Wang X; Pan Y; Li H
    J Neurol; 2024 Aug; 271(8):5326-5332. PubMed ID: 38864881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of myasthenia gravis and myositis induced by pembrolizumab].
    Noda T; Kageyama H; Miura M; Tamura T; Ito H
    Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coexisting of myasthenia gravis and fulminant myocarditis induced by nivolumab in a patient with ureteral epithelial cancer.
    Zhang J; Li J; Zhai L; Lin L
    Neuro Endocrinol Lett; 2021 Oct; 42(6):383-386. PubMed ID: 34713689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment].
    Yao S; Li X; Nong J; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):685-688. PubMed ID: 32752585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitor-Mediated Myasthenia Gravis.
    Ho AK; Cooksley T
    J Emerg Med; 2020 Oct; 59(4):561-562. PubMed ID: 32565169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel uses of complement inhibitors in myasthenia gravis-Two case reports.
    Zadeh S; Price H; Drews R; Bouffard MA; Young LH; Narayanaswami P
    Muscle Nerve; 2024 Mar; 69(3):368-372. PubMed ID: 38205840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis.
    Zhao S; Zhou Y; Sun W; Li Z; Wang C
    Clin Exp Immunol; 2023 Mar; 211(2):85-92. PubMed ID: 36426591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
    Zaremba A; Chorti E; Jockenhöfer F; Bolz S; Sirin S; Glas M; Becker JC; Ugurel S; Roesch A; Schadendorf D; Livingstone E; Hagenacker T; Zimmer L
    J Immunother Cancer; 2019 May; 7(1):141. PubMed ID: 31142383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma.
    Hayakawa N; Kikuchi E; Suzuki S; Oya M
    Int Cancer Conf J; 2020 Jul; 9(3):123-126. PubMed ID: 32582515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.
    Gonzalez NL; Puwanant A; Lu A; Marks SM; Živković SA
    Neuromuscul Disord; 2017 Mar; 27(3):266-268. PubMed ID: 28109638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
    Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
    Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.